8-KShareholder Matters

ELI LILLY & Co 8-K Report, Shareholder Vote Results (May 4, 2023)

Filed May 4, 2023For Securities:LLY

Summary

Eli Lilly and Company (LLY) filed an 8-K report detailing the results of its 2023 Annual Meeting of Shareholders held on May 1, 2023. The report indicates strong shareholder participation, with approximately 90% of outstanding shares represented. Key outcomes include the election of four director nominees to three-year terms and the advisory approval of executive compensation. Shareholders also voted to continue advisory votes on executive compensation on an annual basis and ratified the appointment of Ernst & Young LLP as the independent auditor. Notably, proposals to eliminate the company's classified board structure and to remove supermajority voting provisions did not achieve the required 80% shareholder approval. Several shareholder proposals concerning lobbying activities, patent exclusivity impacts, abortion support risks, diversity and inclusion efforts, and political expenditure reporting were also not approved.

Key Highlights

  • 1Strong shareholder turnout of approximately 90% of outstanding shares at the 2023 Annual Meeting.
  • 2All four director nominees were successfully elected to serve three-year terms.
  • 3Shareholders provided advisory approval for the compensation of named executive officers.
  • 4The company will continue to hold annual advisory votes on executive compensation, as supported by shareholder vote.
  • 5Ernst & Young LLP was ratified as the independent auditor for 2023.
  • 6Proposals to declassify the board and eliminate supermajority voting provisions failed to garner the required 80% shareholder approval.
  • 7Multiple shareholder proposals covering diverse topics such as lobbying, patent strategy, and DEI were not approved.

Frequently Asked Questions

The meeting saw the election of all four director nominees, advisory approval of executive compensation, and ratification of Ernst & Young LLP as the independent auditor. Shareholders also supported continuing annual advisory votes on executive compensation. However, proposals to eliminate the classified board and supermajority voting requirements did not pass.

These proposals did not achieve the required 80% of outstanding shares for approval. While a significant number of shares voted in favor, the threshold set for these specific governance changes was not met.

The advisory vote, often called a 'say-on-pay' vote, allows shareholders to express their opinion on the compensation of the company's top executives. While non-binding, it provides valuable feedback to the board regarding compensation practices. Eli Lilly's shareholders approved this vote, and the company will continue with annual advisory votes.

Based on the provided filing, none of the specific shareholder proposals detailed in items g through m were approved. These proposals covered a range of topics including lobbying activities, patent strategies, political spending, and diversity and inclusion efforts.